Humira and biosimilars — CareFirst (Caremark)

Initial criteria

• Treatment of moderately to severely active Crohn’s disease

Reauthorization criteria

• Remission or positive clinical response showing low disease activity or improvement in abdominal pain/tenderness, diarrhea, body weight, abdominal mass, hematocrit, mucosal appearance (endoscopy, CTE, MRE, intestinal ultrasound), or improvement in Crohn’s Disease Activity Index (CDAI)

Approval duration

12 months